For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch of a first major share buyback in more than a decade suggest ...

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.

Get Our Latest Stock Report on GSK GSK Stock Up 0.8 % GSK opened at $35.35 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50 day simple moving average is ...

Pharmaceuticals giant GlaxoSmithKline has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceuticals giant GlaxoSmithKline (GSK ...